Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Treasury Shares (2018 - 2025)

Historic Treasury Shares for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $3.8 million.

  • Revolution Medicines' Treasury Shares rose 2949.01% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 2949.01%. This contributed to the annual value of $2.9 million for FY2024, which is 3187.23% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Treasury Shares is $3.8 million, which was up 2949.01% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Treasury Shares ranged from a high of $3.8 million in Q3 2025 and a low of $272.0 during Q4 2022
  • Moreover, its 5-year median value for Treasury Shares was $2.1 million (2023), whereas its average is $1.8 million.
  • Per our database at Business Quant, Revolution Medicines' Treasury Shares plummeted by 9997.45% in 2023 and then soared by 110250481.1% in 2024.
  • Over the past 5 years, Revolution Medicines' Treasury Shares (Quarter) stood at $5793.0 in 2021, then plummeted by 95.3% to $272.0 in 2022, then surged by 794483.46% to $2.2 million in 2023, then surged by 31.87% to $2.9 million in 2024, then surged by 34.82% to $3.8 million in 2025.
  • Its Treasury Shares stands at $3.8 million for Q3 2025, versus $3.8 million for Q2 2025 and $3.8 million for Q1 2025.